Marshall Edwards, Inc. (NASDAQ: MSHL) is planning to release preliminary results from a Phase II clinical trial of oral phenoxodiol in patients with early and advanced stage prostate cancer. The results will be presented by the Yale researchers, who were responsible for the study, at the ASCO Genitourinary Cancers Symposium in Orlando, Florida; February 26-28, 2009 became available in abstract form on the ASCO website yesterday.

Kevin Kelly, DO, Associate Director, Solid Tumor Investigation, Yale Cancer Center, led the research.

The information will be released at a poster presentation which will review data supporting the anti-tumor effects of phenoxodiol as studied in patients with advanced prostate cancer (Group A) and in patients with early stage, pre-metastatic disease where prostate specific antigen (PSA) levels were rising after radical prostatectomy or radiat